title: [A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor].
authors.affiliation: Inserm UMR 1043, CNRS UMR 5282, Université de Toulouse, Centre de Physiopathologie de Toulouse-Purpan, Hôpital Purpan, Bât. A, BP 3028, 31024 Toulouse Cedex 3, France. philippe.le-bouteiller@inserm.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Le Bouteiller
authors.forename: Julie
authors.initials: J
authors.lastname: Tabiasco
authors.forename: Jérôme
authors.initials: J
authors.lastname: Giustiniani
authors.forename: Armand
authors.initials: A
authors.lastname: Bensussan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D016510:Corneal Neovascularization / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D005354:Fibrosarcoma / Q000098:blood supply / Q000188:drug therapy / Q000276:immunology; D058851:GPI-Linked Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000276:immunology; D011817:Rabbits; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors* / Q000276:immunology; D013045:Species Specificity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018906:Antineoplastic Agents, Alkylating; C114505:CD160 protein, human; D058851:GPI-Linked Proteins; D011971:Receptors, Immunologic; D003520:Cyclophosphamide